Lineweaver Wealth Advisors LLC Acquires 909 Shares of Johnson & Johnson (NYSE:JNJ)

Lineweaver Wealth Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 6.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 15,816 shares of the company’s stock after purchasing an additional 909 shares during the period. Johnson & Johnson accounts for 0.8% of Lineweaver Wealth Advisors LLC’s investment portfolio, making the stock its 27th largest holding. Lineweaver Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,579,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC increased its holdings in shares of Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the last quarter. Goodman Advisory Group LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at $39,000. Cardinal Capital Management Inc. increased its holdings in shares of Johnson & Johnson by 333.3% in the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the last quarter. First Bank & Trust increased its holdings in shares of Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after purchasing an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at $84,000. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Sanford C. Bernstein reduced their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Raymond James reduced their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Citigroup boosted their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Finally, Morgan Stanley reduced their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Stock Down 0.3 %

JNJ stock opened at $168.31 on Tuesday. The stock has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a 50-day moving average price of $176.07 and a 200-day moving average price of $171.13.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Insider Transactions at Johnson & Johnson

In other news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Ashley Mcevoy sold 73,323 shares of the company’s stock in a transaction that occurred on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 233,611 shares of company stock valued at $40,960,735. 0.35% of the stock is currently owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.